News
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...
Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
Lucid soars after announcing a self-driving partnership with Uber Technologies and Nuro, Taiwan Semiconductor Manufacturing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback